Vizual Stocks works best vertically on mobile.
VizualStocks APIOperating KPI and segment definitions available for Eli Lilly (LLY) through the VizualStocks API.
Lilly revenue attributed to China based on the location of the customer or other contracting party, including net product sales and collaboration or other revenue. The figure reflects realized local pricing as well as demand, including reimbursement changes such as Mounjaro's addition to China's National Reimbursement Drug List.
chinaRevenueRevenue from Lilly's Cardiometabolic Health portfolio, including Mounjaro, Zepbound, Jardiance, Trulicity and other diabetes, obesity and related medicines. The configured Diabetes name is outdated because this category now includes obesity treatment and other cardiometabolic products, not diabetes drugs alone.
diabetesRevenueLilly revenue attributed to customers or other contracting parties located in Europe. It includes net product sales and collaboration or other revenue, so it is broader than pharmacy sales to patients alone.
europeRevenueRevenue from Lilly's immunology medicines, led by Taltz for autoimmune diseases and newer products such as Ebglyss for atopic dermatitis and Omvoh for inflammatory bowel disease. It groups products by therapeutic area rather than by geography or commercial channel.
immunologyRevenueLilly revenue attributed to customers or other contracting parties located in Japan. It includes net product sales and collaboration or other revenue, so it is broader than pharmacy sales to patients alone.
japanRevenueRevenue from Lilly's neuroscience medicines, including Kisunla for Alzheimer's disease and Emgality for migraine prevention, along with other products assigned to the therapeutic area. It tracks the commercial scale of Lilly's brain-health portfolio rather than the value or size of its clinical pipeline.
neuroscienceRevenueRevenue from Lilly's cancer medicines, including Verzenio, Cyramza, Erbitux, Tyvyt, Jaypirca and other oncology products. The total combines U.S. and international sales across multiple tumor types rather than representing a single drug or cancer indication.
oncologyRevenueLilly revenue from customers or other contracting parties outside the United States, Europe, China and Japan, reported by the issuer as Rest of World. It includes net product sales and collaboration or other revenue across all remaining international markets.
otherForeignCountriesRevenueRevenue from Lilly medicines and collaboration or other items not assigned to Cardiometabolic Health, Oncology, Immunology or Neuroscience in the therapeutic-area table. It is the issuer's residual product category, not revenue from a product named Other.
otherProductRevenueSmall reconciliation difference between Lilly's total revenue and the sum of the configured therapeutic-area categories. It is generally zero or a rounding amount and should not be interpreted as a distinct operating business or product family.
otherRevenueSmall reconciliation difference between Lilly's total revenue and the sum of the configured U.S., Europe, China, Japan and Rest of World amounts. It is generally zero or a rounding amount, not sales from an additional geographic market.
otherRevenueByGeographyPercentage-point effect of currency translation on Lilly's year-over-year revenue growth when non-U.S. sales are converted into U.S. dollars. It isolates exchange-rate movement from changes in transaction volume and realized selling prices.
revenueChangeDueToForeignExchangePercentage-point contribution of realized selling-price changes to Lilly's year-over-year revenue growth, after rebates, discounts and other price concessions. It is separate from prescription or unit volume and foreign-exchange effects and can be negative even when total revenue grows rapidly.
revenueChangeDueToPricePercentage-point contribution of transaction volume to Eli Lilly's period-over-period revenue change, as reported in the company's price-rate-volume analysis.
revenueChangeDueToTransactionsLilly revenue attributed to customers or other contracting parties located in the United States. It includes net product sales and collaboration or other revenue, with reported amounts reflecting rebates, discounts and other U.S. price concessions.
unitedStatesRevenue